Dr. Roland Bruderer | Computational Proteomics | Outstanding Scientist Award

Dr. Roland Bruderer | Computational Proteomics | Outstanding Scientist Award 

BIOGNOSYS AG | Switzerland 

Roland Bruderer is a leading proteomics researcher specializing in mass spectrometry–based analytical technologies and advanced LC-MS workflows for large-scale protein analysis. His research focuses on the development of robust, high-throughput proteomics platforms that enable deep and reproducible profiling of complex biological samples. He has made seminal contributions to data-independent acquisition strategies, particularly SWATH mass spectrometry, significantly expanding the depth and consistency of whole-proteome measurements. His work has demonstrated the feasibility of identifying and quantifying more than ten thousand proteins in single analytical runs, setting new standards for proteome coverage. In addition, he has contributed to quality control and bioinformatics solutions for immunopeptidomics and large-scale proteomics datasets. His research addresses protein interactions, post-translational modifications, and metabolite–protein interactions using innovative mass spectrometry approaches. By integrating analytical chemistry with molecular and cell biology, his work supports applications in systems biology, translational research, and precision medicine. He is recognized for translating complex methodological innovations into scalable, industry-ready proteomics workflows.

Citation Metrics (Scopus)

3000
2000
1000
0

Citations
2,838

Documents
34

h-index
20

Citations

Documents

h-index



View Scopus Profile

Featured Publications

Prof. Dr.  jawad oumerzouk | Computational Neuroscience | Research Excellence Award

Prof. Dr.  jawad oumerzouk | Computational Neuroscience | Research Excellence Award 

mohamed V instruction military hospital | Morocco 

Professor Jawad Oumerzouk is a neurologist and academic researcher whose work focuses on advancing clinical understanding and management of neurological disorders, with particular emphasis on multiple sclerosis and immune-mediated diseases of the central nervous system. His research integrates real-world clinical data with evidence-based therapeutic evaluation to improve patient outcomes in resource-diverse healthcare settings. He has contributed to multicenter observational studies assessing the effectiveness and safety of disease-modifying therapies, notably anti-CD20 monoclonal antibodies such as rituximab. Through his scholarly publications and collaborative research initiatives, he has strengthened regional neurological research capacity and supported the translation of clinical research findings into routine neurological practice. His work also emphasizes optimizing treatment strategies using accessible biologic therapies. He contributes to strengthening clinical research standards through data-driven neurological studies. His research supports the development of context-relevant clinical evidence. Collectively, his contributions advance modern neuroimmunology and patient-centered neurological care.

Publications

Effectiveness of rituximab in the treatment of multiple sclerosis: A multicenter, retrospective, observational study in Morocco.
Multiple Sclerosis and Related Disorders, 2025.

Neurological complications of giant cell arteritis: A study of 15 cases and a review of the literature.
Journal Français d’Ophtalmologie, 2023.